How do I buy Supernus Pharmaceuticals Inc (SUPN) stock?

Buying Supernus Pharmaceuticals Inc (SUPN) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "SUPN", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy SUPN by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if SUPN is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Supernus Pharmaceuticals Inc (SUPN) Stock

NMQ · SUPN

Trade SUPN

43.62

Fundamentals

Market cap

$2.48B

Price / Earnings ratio

-22.9x

Price / Sales ratio

3.0x

Price / Book ratio

2.4x

Return on assets

-2.0%

Ex-Dividend date

N/A

Last payment date

N/A

Dividend amount

$0.00

Dividend yield

0.00%

Debt / Equity ratio

N/A

Technicals

OscillatorsStrong Buy5 Indicators

Moving AveragesSell12 Indicators

Analyst Ratings

Strong Sell0

Sell0

Neutral0

Buy1

Strong Buy0

Financials

Performance

Revenue

Net income

Net margin %

2025

863M569M285M0

Debt & Balance Sheet

Total assets

Total liabilities

2025

2B1B575M0

Revenue to Profit

2025

$719.0M

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-38.5M

Net income

Earnings

EPS forecast

Actual EPS

$0.40

Q1FY26

$0.59

Q2FY26

The market is expecting earnings per share of $0.59 for this quarter. The company has not yet shared when it is announcing earnings.

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees778

CEOMr. Jack A. Khattar M.B.A.

IPO DateMay 1, 2012

HeadquartersRockville, MD

Key Executives

Name	Title	Year Born
Mr. Jack A. Khattar M.B.A.	Founder, President, CEO, Secretary & Director	1961
Mr. Timothy C. Dec	Senior VP & CFO	1959
Dr. Padmanabh P. Bhatt Ph.D.	Chief Scientific Officer & Senior VP of Intellectual Property	1957
Mr. Frank Mottola	Senior VP & Chief Technology Operations Officer	1972
Dr. Jonathan Rubin M.B.A., M.D.	Senior VP of Research & Development and Chief Medical Officer	1961
Mr. Kevin T. Anderson Esq.	Compliance Officer	1962
Mr. Taylor Raiford	Senior Vice President of Sales	—
Dr. William Todd Horich M.B.A., Ph.D.	Senior VP & Chief Commercial Officer	1973
Mr. Jeff Bozick	Senior Vice President of Supply Chain	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021									-0.7	+9.7	-1.2	-5.5
2022	+2.6	+0.6	+8.8	-13.3	-3.5	+3.4	+8.2	+8.7	-3.4	+2.3	+7.0	-3.6
2023	+9.4	-9.6	-7.7	+1.2	-10.3	-8.8	+2.6	+0.5	-15.1	-12.1	+14.0	+4.9
2024	-0.2	+6.6	+10.0	-10.2	-9.8	-3.1	+12.3	+18.9	-10.2	+6.5	+7.7	-3.1
2025	+5.3	-14.2	+3.2	+2.5	-2.3	-1.2	+10.3	+27.1	+7.3	+14.8	-18.2	+11.2
2026	-2.6	+12.2	-6.2	-6.7	-3.5	+3.9	-5.9	-3.9	-2.5

FAQ

Buying Supernus Pharmaceuticals Inc (SUPN) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "SUPN", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy SUPN by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Supernus Pharmaceuticals Inc from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Supernus Pharmaceuticals Inc (SUPN) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track SUPN's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Supernus Pharmaceuticals Inc (SUPN) Stock

Fundamentals

Recent news

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

New Strong Buy Stocks for August 7th

New Strong Buy Stocks for August 7th

Best Value Stocks to Buy for August 7th

Best Value Stocks to Buy for August 7th

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

About Supernus Pharmaceuticals Inc

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade